Figure 1.

Whole-exome sequencing in baseline tumor tissues.

(a) Study workflow. (b) Mutation genes detected in baseline tumor samples. Upper graph, tumor mutation burden. Most mutations were non-synonymous. Middle graph, mutation genes at top 30 mutation occurrence in all samples were illustrated. A total of 16.89 months, median overall survival time. (c) Gene mutations enriched in representative signaling pathways in baseline tumor samples. (d and e) Kaplan–Meier estimates of overall survival (d) and progressive-free survival (e) among patients with or without PI3K pathway mutation. Cutoff value, Youden index of the ROC curve. N = 16. P < .05, significant difference. IF, immunofluorescence. TCR, T cell receptor. WES, whole-exome sequencing. TMB, tumor mutation burden. TNB, tumor neoantigen.